Menlo Therapeutics Inc. added new faces to its stable of investors in a $50 million series C designed to move serlopitant, the company's NK-1 receptor antagonist, into a pivotal program as a once-daily oral treatment for the lead indication of chronic pruritus, or itch, associated with the skin disease prurigo nodularis. The company, aptly based in Menlo Park, Calif., also is advancing serlopitant to treat chronic pruritus associated with the broader indications of atopic dermatitis and psoriasis and to treat refractory chronic cough.